Impaired differentiation and cytotoxicity of natural killer cells in systemic lupus erythematosus

Arthritis and Rheumatism

Volumn 60, Issue 6, 2009, Pages 1753-1763

  Park, Yong Wook ^a   Kee, Seung Jung ^a   Cho, Young Nan ^a   Lee, Eun Hee ^b   Lee, Hwa Youn ^b   Kim, Eun Mi ^b   Shin, Min Ho ^a   Park, Jeong Jin ^a   Kim, Tae Jong ^a   Lee, Shin Seok ^a   Yoo, Dae Hyun ^c   Kang, Hyung Sik ^b  

^a Chonnam National University Medical School   (South Korea)

^b Chonnam National University   (South Korea)

^c Hanyang University Hospital for Rheumatic Diseases   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; GRANZYME; INTERLEUKIN 2 RECEPTOR BETA; PERFORIN;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BEHCET DISEASE; BONE MARROW; CELL DIFFERENTIATION; CELL STRAIN K 562; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOREGULATION; IN VITRO STUDY; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOKINE ACTIVATED KILLER CELL; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA;

ADULT; APOPTOSIS; ARTHRITIS, RHEUMATOID; BEHCET SYNDROME; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GRANZYMES; HUMANS; KILLER CELLS, LYMPHOKINE-ACTIVATED; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; MIDDLE AGED; PERFORIN; RECEPTORS, INTERLEUKIN-2; SPONDYLITIS, ANKYLOSING; THROMBOCYTOPENIA;

EID: 66449101426     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.24556     Document Type: Article

References (49)

1. Raulet DH. Development and tolerance of natural killer cells. Curr Opin Immunol 1999;11:129-134
2. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989;47:187-376. (Pubitemid 20010960)
3. Colucci F, Caligiuri MA, Di Santo JP. What does it take to make a natural killer? Nat Rev Immunol 2003;3:413-425
4. Iizuka K, Chaplin DD, Wang Y, Wu Q, Pegg LE, Yokoyama WM, et al. Requirement for membrane lymphotoxin in natural killer cell development. Proc Natl Acad Sci U S A 1999;96:6336-6340 (Pubitemid 29256666)
5. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon: lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 1982;155:1823-1841 (Pubitemid 12074218)
6. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 1999;17:189-220. (Pubitemid 29241123)
7. Seaman WE, Sleisenger M, Eriksson E, Koo GC. Depletion of natural killer cells in mice by monoclonal antibody to NK-1.1: reduction in host defense against malignancy without loss of cellular or humoral immunity. J Immunol 1987;138:4539-4544 (Pubitemid 17090439)
8. Horwitz DA, Gray JD, Ohtsuka K, Hirokawa M, Takahashi T. The immunoregulatory effects of NK cells: the role of TGF-β and implications for autoimmunity. Immunol Today 1997;18:538-542 (Pubitemid 127772687)
9. Takeda K, Dennert G. The development of autoimmunity in C57BL/6 lpr mice correlates with the disappearance of natural killer type 1-positive cells: evidence for their suppressive action on bone marrow stem cell proliferation, B cell immunoglobulin secretion, and autoimmune symptoms. J Exp Med 1993;177:155-164 (Pubitemid 23008095)
10. Hoffman T. Natural killer function in systemic lupus erythematosus. Arthritis Rheum 1980;23:30-35 (Pubitemid 10214766)
11. Goto M, Tanimoto K, Horiuchi Y. Natural cell mediated cytotoxicity in systemic lupus erythematosus: suppression by antilymphocyte antibody. Arthritis Rheum 1980;23:1274-1281 (Pubitemid 11234044)
12. Katz P, Zaytoun AM, Lee JH Jr, Panush RS, Longley S. Abnormal natural killer cell activity in systemic lupus erythematosus: an intrinsic defect in the lytic event. J Immunol 1982;129:1966-1971
13. Sibbitt WL Jr, Froelich CJ, Bankhurst AD. Abnormal interferon modulation of natural cytotoxicity in systemic lupus erythematosus: relation to suppressive serum factors. Arthritis Rheum 1983;26:1452-1459 (Pubitemid 14215799)
14. Sibbitt WL Jr, Mathews PM, Bankhurst AD. Natural killer cell in systemic lupus erythematosus: defects in effector lytic activity and response to interferon and interferon inducers. J Clin Invest 1983;71:1230-1239
15. Egan ML, Mendelsohn SL, Abo T, Balch CM. Natural killer cells in systemic lupus erythematosus: abnormal numbers and functional immaturity of HNK-1+ cells. Arthritis Rheum 1983;26:623-629
16. Erkeller-Yusel F, Hulstaart F, Hannet I, Isenberg D, Lydyard P. Lymphocyte subsets in a large cohort of patients with systemic lupus erythematosus. Lupus 1993;2:227-231 (Pubitemid 23295636)
17. Yabuhara A, Yang FC, Nakazawa T, Iwasaki Y, Mori T, Koike K, et al. A killing defect of natural killer cells as an underlying immunologic abnormality in childhood systemic lupus erythematosus. J Rheumatol 1996;23:171-177 (Pubitemid 26037216)
18. Green MR, Kennell AS, Larche MJ, Seifert MH, Isenberg DA, Salaman MR. Natural killer cell activity in families of patients with systemic lupus erythematosus: demonstration of a killing defect in patients. Clin Exp Immunol 2005;141:165-173 (Pubitemid 40904654)
19. Tiefenthaler M, Bacher N, Linert H, Muhlmann O, Hofer S, Sepp N, et al. Apoptosis of CD34+ cells after incubation with sera of leukopenic patients with systemic lupus erythematosus. Lupus 2003;12:471-478 (Pubitemid 36830122)
20. Papadaki HA, Boumpas DT, Gibson FM, Jayne DR, Axford JS, Gordon-Smith EC, et al. Increased apoptosis of bone marrow CD34+ cells and impaired function of bone marrow stromal cells in patients with systemic lupus erythematosus. Br J Haematol 2001;115:167-174 (Pubitemid 32995113)
21. Westerweel PE, Luijten RK, Hoefer IE, Koomans HA, Derksen RH, Verhaar MC. Haematopoietic and endothelial progenitor cells are deficient in quiescent systemic lupus erythematosus. Ann Rheum Dis 2007;66:865-870 (Pubitemid 46999785)
22. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-1277 (Pubitemid 13221242)
23. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324
24. International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease [review]. Lancet 1990;335:1078-1080
25. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-368 (Pubitemid 14134775)
26. Godoy-Ramirez K, Franck K, Gaines H. A novel method for the simultaneous assessment of natural killer cell conjugate formation and cytotoxicity at the single-cell level by multi-parameter flow cytometry. J Immunol Methods 2000;239:35-44. (Pubitemid 30256016)
27. Grzywacz B, Kataria N, Sikora M, Oostendorp RA, Dzierzak EA, Blazar BR, et al. Coordinated acquisition of inhibitory and activating receptors and functional properties by developing human natural killer cells. Blood 2006;108:3824-3833 (Pubitemid 44864565)
28. Kang HS, Kim EM, Lee S, Yoon SR, Kawamura T, Lee YC, et al. Stage-dependent gene expression profiles during natural killer cell development. Genomics 2005;86:551-565 (Pubitemid 41416788)
29. Gonzalez-Amaro R, Alcocer-Varela J, Alarcon-Segovia D. Natural killer cell activity in the systemic connective tissue diseases. J Rheumatol 1988;15:1223-1228 (Pubitemid 18221558)
30. Struyf NJ, Snoeck HW, Bridts CH, De Clerck LS, Stevens WJ. Natural killer cell activity in Sjögren's syndrome and systemic lupus erythematosus: stimulation with interferons and interleukin-2 and correlation with immune complexes. Ann Rheum Dis 1990;49:690-693 (Pubitemid 20279120)
31. Suzuki H, Duncan GS, Takimoto H, Mak TW. Abnormal development of intestinal intraepithelial lymphocytes and peripheral natural killer cells in mice lacking the IL-2 receptor β chain. J Exp Med 1997;185:499-505. (Pubitemid 27078368)
32. Huntington ND, Vosshenrich CA, Di Santo JP. Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat Rev Immunol 2007;7:703-714 (Pubitemid 47327395)
33. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992;35:630-640
34. Shibuya A, Nagayoshi K, Nakamura K, Nakauchi H. Lymphokine requirement for the generation of natural killer cells from CD34+ hematopoietic progenitor cells. Blood 1995;85:3538-3546
35. + human natural killer cell progenitor that responds to interleukin-15. Blood 1998;92:3647-3657
36. Ortaldo JR, Mason AT, O'Shea JJ. Receptor-induced death in human natural killer cells: involvement of CD16. J Exp Med 1995;181:339-344
37. Shibatomi K, Ida H, Yamasaki S, Nakashima T, Origuchi T, Kawakami A, et al. A novel role for interleukin-18 in human natural killer cell death: high serum levels and low natural killer cell numbers in patients with systemic autoimmune diseases. Arthritis Rheum 2001;44:884-892 (Pubitemid 32319781)
38. Sibbitt WL, Froelich CJ, Bankhurst AD. Natural cytotoxicity in systemic lupus erythematosus: mechanisms of suppression by inhibitory serum factors. Clin Exp Immunol 1983;53:363-370
39. Caligiuri MA, Zmuidzinas A, Manley TJ, Levine H, Smith KA, Ritz J. Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. J Exp Med 1990;171:1509-1526 (Pubitemid 20167547)
40. Phillips JH, Takeshita T, Sugamura K, Lanier LL. Activation of natural killer cells via the p75 interleukin 2 receptor. J Exp Med 1989;170:291-296 (Pubitemid 19179712)
41. Siegel JP, Sharon M, Smith PL, Leonard WJ. The IL-2 receptor β chain (p70): role in mediating signals for LAK, NK, and proliferative activities. Science 1987;238:75-78
42. Carson WE, Giri JG, Lindemann MJ, Linett ML, Ahdieh M, Paxton R, et al. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med 1994;180:1395-1403 (Pubitemid 24289613)
43. Giri JG, Ahdieh M, Eisenman J, Shanebeck K, Grabstein K, Kumaki S, et al. Utilization of the β and γ chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J 1994;13:2822-2830 (Pubitemid 24191692)
44. Ishida H, Kumagai S, Umehara H, Sano H, Tagaya Y, Yodoi J, et al. Impaired expression of high affinity interleukin 2 receptor on activated lymphocytes from patients with systemic lupus erythematosus. J Immunol 1987;139:1070-1074 (Pubitemid 17134172)
45. Tanaka T, Saiki O, Negoro S, Igarashi T, Kuritani T, Hara H, et al. Decreased expression of interleukin-2 binding molecules (p70/75) in T cells from patients with systemic lupus erythematosus. Arthritis Rheum 1989;32:552-559 (Pubitemid 19146695)
46. Erkeller-Yuksel FM, Lydyard PM, Isenberg DA. Lack of NK cells in lupus patients with renal involvement. Lupus 1997;6:708-712 (Pubitemid 27511288)
47. Vance BA, Huizinga TW, Wardwell K, Guyre PM. Binding of monomeric human IgG defines an expression polymorphism of FcγRIII on large granular lymphocyte/natural killer cells. J Immunol 1993;151:6429-6439 (Pubitemid 23340389)
48. Wu J, Edberg JC, Redecha PB, Bansal V, Guyre PM, Coleman K, et al. A novel polymorphism of FcγRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 1997;100:1059-1070 (Pubitemid 27386289)
49. Jawahar S, Moody C, Chan M, Finberg R, Geha R, Chatila T. Natural killer (NK) cell deficiency associated with an epitope-deficient Fc receptor type IIIA (CD16-II). Clin Exp Immunol 1996;103:408-413